1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow devimistat: new trials by email Literature Review of devimistat trials Research Report on devimistat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine - Relapsed/Refractory Acute Myeloid Leukemia | Phase 3 | Terminated | Cornerstone Pharmaceuticals | 200 | 2018-11-12 | 2023-02-08 |
| Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas CPI 613, mFolfirinox, Folfirinox - Pancreatic Cancer Metastatic | Phase 3 | Completed | Cornerstone Pharmaceuticals | 528 | 2018-11-09 | 2023-01-03 |
Cornerstone Pharmaceuticals (2)
Belgium (2) · France (2) · Germany (2) · South Korea (2) · United States (2) · Australia (1) · Austria (1) · Israel (1) · Poland (1) · Spain (1)
Jorge E Cortes, MD (1) · Philip A Philip, MD, PhD, FRCP (1)